Beta Bionics Q2 net sales up 54% to $23.2M; raises full-year guidance

Beta Bionics, Inc.

2025-Q2 EPS reported -$1.23 revenue$40,877,000

Net sales $23.2M (+54% YoY); DME channel $18.6M (+31%), PBP channel $4.6M (+498%).
Installed base 24,085 users (+200%); new patient starts 4,934 (+57%), 71% from MDI.
Net loss $16.9M (negative 73% of sales) vs $14.5M (negative 96%) in Q2 2024.
Adjusted EBITDA -$14.5M (negative 63% of sales) vs -$10.0M (negative 66%).
Cash and investments $280.9M as of June 30; raised full-year 2025 revenue and adjusted EBITDA guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.